July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
FDA-approved drugs to combat inflammation and metabolic dysfunction in macular degenerations
Author Affiliations & Notes
  • Aparna Lakkaraju
    School of Medicine, University of California, San Francisco, San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Aparna Lakkaraju, None
  • Footnotes
    Support  NIH Grant EY023299
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4215. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Aparna Lakkaraju; FDA-approved drugs to combat inflammation and metabolic dysfunction in macular degenerations. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4215.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : Damage to the retinal pigment epithelium (RPE) is an initiating factor that eventually culminates in vision loss in macular degenerations. Therefore, drugs that preserve RPE health and function could halt AMD at its earliest stages. We have recently identified ceramide as a novel drug target in AMD because it regulates complement activity, metabolic dysfunction and inflammation, three pathways implicated in AMD pathogenesis. This presentation will discuss our recent studies showing that clinically approved drugs that decrease RPE ceramide correct multiple dysfunctional pathways implicated in early AMD.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.